belantamab mafodotin-blmf (Blenrep)
belantamab mafodotin-blmf is an FDA-licensed reference biologic from GlaxoSmithKline LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Blenrep belantamab mafodotin-blmf
GlaxoSmithKline LLC
- Approved
- Oct 23, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for belantamab mafodotin-blmf, in chronological order.
Reference approval
Approval date of the reference belantamab mafodotin-blmf product.
7 mo ago
Frequently asked questions
Are there biosimilars approved for belantamab mafodotin-blmf (Blenrep)?
No 351(k) biosimilars or interchangeable biosimilars referencing belantamab mafodotin-blmf are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.